Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

分组1 - Atara Biotherapeutics reported a quarterly loss of $1.19 per share, significantly better than the Zacks Consensus Estimate of a loss of$3.82, and an improvement from a loss of $14 per share a year ago, resulting in an earnings surprise of 68.85$32.75 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 150.02%, compared to revenues of $4.25 million in the same quarter last year [2] - Atara Biotherapeutics has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in performance [2] 分组2 - The stock has underperformed the market, losing approximately 48.9% since the beginning of the year, while the S&P 500 has declined by only 2.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.94 on revenues of$0.2 million, and for the current fiscal year, it is -$10.32 on revenues of$64.5 million [7] - The Medical - Biomedical and Genetics industry, to which Atara belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable industry outlook [8]